1290048-20-2

Upstream product

• 161494-74-2 (R)-2-(benzyloxycarbonylamino)propyl methanesulfonate 
• 61425-27-2 ((R)-2-hydroxy-1-methyl-ethyl)-carbamic acid benzyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 501-53-1 benzyl chloroformate 
• 156-87-6 propan-1-ol-3-amine 
• 83197-70-0 (S)-2-(benzyloxycarbonylamino)propyl methanesulfonate 

Downstream Products

• 1290048-18-8 3-{(R)-4-[(E)-3-(3-chloro-phenyl)-acryloyl]-3-methyl-7-oxo-[1,4]diazepan-1-yl}-propionic acid 
• 1290048-22-4 (R)-1-[(E)-3-(3-Chloro-phenyl)-acryloyl]-4-(3-hydroxy-propyl)-2-methyl-[1,4]diazepan-5-one 
• 1290050-11-1 (R)-1-[(E)-3-(3-chloro-phenyl)-acryloyl]-2-methyl-4-(3-oxo-3-piperidin-1-yl-propyl)-[1,4]diazepan-5-one 
• 1290048-21-3 3-{{(R)-2-[tert-butoxycarbonyl-(3-hydroxy-propyl)-amino]-1-methyl-ethyl}-[(E)-3-(3-chloro-phenyl)-acryloyl]-amino}-propionic acid methyl ester 

Relevant academic research and scientific papers

RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF

Provided are a Rho kinase inhibitor, a method for preparing same and the uses thereof. The Rho kinase inhibitor designates a compound of Formula I, a stereoisomer thereof or pharmaceutically acceptable salt thereof. The Rho kinase inhibitor promotes endothelial cells and endothelin expression, prostenin expression, and vascular factors NO synthesis and secretion, has a promoting effect on proprostin expression independently of the doses used, shows lower toxicity, while being safer.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9, and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.

DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS

The invention is concerned with novel bicyclic compounds of Formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9 and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.